accountAmgen Inc.’s bone-strengthening injection denosumab, for postmenopausal women with osteoporosis, will be the first biotechnology drug likely to be prescribed by patients’ primary physicians rather than specialists. Shares rose today the most in about 11 months.
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Amgen Drug Becomes First Biologic for Primary Care (Update3)
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account